Teleflex Reports Third Quarter 2020 Results
Teleflex reported third quarter 2020 revenues of $628.3 million, a decline of 3.1% year-over-year. GAAP diluted EPS was $2.46, down 49.3% from $4.85 in the previous year. Adjusted EPS fell 6.7% to $2.77. Revenue was adversely affected by the COVID-19 pandemic, with an estimated $78 million impact, contributing to a 12% revenue loss. Despite these challenges, growth was noted in the Interventional Urology sector and Vascular Access products. The company announced an acquisition of Z-Medica, LLC, expected to enhance earnings per share in 2021.
- Vascular Access products revenue increased 7.6% to $160 million.
- Interventional Urology business showed recovery with 11.1% revenue growth.
- Acquisition of Z-Medica expected to be accretive to earnings in 2021.
- Total revenue decreased 3.1% year-over-year.
- GAAP EPS dropped 49.3% compared to prior year.
- Significant revenue impact estimated at $78 million due to COVID-19.
Third Quarter Revenues of
Third Quarter GAAP Diluted EPS from Continuing Operations of
Third Quarter Adjusted Diluted EPS from Continuing Operations of
Not Reinstating 2020 Financial Guidance due to COVID-19 Pandemic
WAYNE, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 27, 2020.
Third quarter 2020 net revenues were
Third quarter 2020 GAAP earnings per share from continuing operations decreased
Liam Kelly, Chairman, President and Chief Executive Officer, said, “Our third quarter results reflect improving trends across many of our global product categories, led by a faster-than-expected recovery within our Interventional Urology business, and continued strength within our Vascular Access product sales. From a regional perspective, we saw particular strength within the Americas, as the pace of recovery in the United States during the third quarter was encouraging."
Mr. Kelly continued, "In addition to the significant sequential improvement in our constant currency revenue performance, we also saw a significant improvement within our adjusted gross and operating margins, as well as our adjusted earnings per share, as compared to the second quarter of the year. And while we are not reinstating full year 2020 financial guidance, we continue to believe that we will see continued sequential improvement during the fourth quarter of the year as compared to our third quarter 2020 results."
Mr. Kelly concluded, "Lastly, I am pleased to announce that during October we signed a definitive agreement to acquire Z-Medica, LLC, a market leader in hemostatic products. We are excited about this acquisition, given Z-Medica's revenue growth, gross and operating margin profile, all of which are above our average, and our expectation that the acquisition will be accretive to our adjusted earnings per share in 2021."
NET REVENUE BY SEGMENT
The following tables and commentary provide information regarding net revenues in each of the Company's reportable operating segments for the three and nine months ended September 29, 2019 and September 27, 2020 on both a GAAP and constant currency basis. The discussion below the tables of the principal factors behind changes in net revenues for the three months ended September 27, 2020 as compared to the prior year period applies to both GAAP revenue and constant currency revenue, although GAAP revenue also was affected by foreign currency exchange rate fluctuations, as indicated in the "Currency Impact" column of the table.
| Three Months Ended | % Increase / (Decrease) | |||||||||||||||
| September 27, 2020 | September 29, 2019 | Total Sales Growth | Currency Impact | Constant Currency Revenue Growth | ||||||||||||
| Americas | $ | 375.0 | $ | 374.5 | 0.1 | % | (0.3 | )% | 0.4 | % | ||||||
| EMEA | 135.7 | 140.5 | (3.5 | )% | 3.5 | % | (7.0 | )% | ||||||||
| Asia | 68.2 | 77.9 | (12.4 | )% | 1.8 | % | (14.2 | )% | ||||||||
| OEM | 49.4 | 55.4 | (10.9 | )% | 0.9 | % | (11.8 | )% | ||||||||
| Total | $ | 628.3 | $ | 648.3 | (3.1 | )% | 1.0 | % | (4.1 | )% | ||||||
| Nine Months Ended | % Increase / (Decrease) | |||||||||||||||
| September 27, 2020 | September 29, 2019 | Total Sales Growth | Currency Impact | Constant Currency Revenue Growth | ||||||||||||
| Americas | $ | 1,045.6 | $ | 1,092.3 | (4.3 | )% | (0.3 | )% | (4.0 | )% | ||||||
| EMEA | 423.4 | 442.1 | (4.2 | )% | (0.6 | )% | (3.6 | )% | ||||||||
| Asia | 188.4 | 213.9 | (11.9 | )% | (1.3 | )% | (10.6 | )% | ||||||||
| OEM | 168.6 | 166.1 | 1.5 | % | — | % | 1.5 | % | ||||||||
| Total | $ | 1,826.0 | $ | 1,914.4 | (4.6 | )% | (0.4 | )% | (4.2 | )% | ||||||
Americas third quarter 2020 net revenues were
EMEA third quarter 2020 net revenues were
Asia third quarter 2020 net revenues were
OEM third quarter 2020 net revenues were
NET REVENUE BY GLOBAL PRODUCT CATEGORY
The following tables and commentary provide information regarding net revenues in each of the Company's global product categories for the three months and nine months ended September 29, 2019 and September 27, 2020 on both a GAAP and constant currency basis.
| Three Months Ended | % Increase / (Decrease) | ||||||||||||
| September 27, 2020 | September 29, 2019 | Total Revenue Growth | Currency Impact | Constant Currency Revenue Growth | |||||||||
| Vascular Access | $ | 160.0 | $ | 148.7 | 7.6 | % | 0.8 | % | 6.8 | % | |||
| Interventional | 93.2 | 106.9 | (12.8 | )% | 0.7 | % | (13.5 | )% | |||||
| Anesthesia | 75.7 | 87.1 | (13.2 | )% | 1.2 | % | (14.4 | )% | |||||
| Surgical | 82.2 | 92.6 | (11.2 | )% | 1.1 | % | (12.3 | )% | |||||
| Interventional Urology | 81.8 | 73.6 | 11.1 | % | 0.1 | % | 11.0 | % | |||||
| OEM | 49.4 | 55.4 | (10.9 | )% | 0.9 | % | (11.8 | )% | |||||
| Other | 86.0 | 83.9 | 2.5 | % | 2.0 | % | 0.5 | % | |||||
| Total | $ | 628.3 | $ | 648.3 | (3.1 | )% | 1.0 | % | (4.1 | )% | |||
| Nine Months Ended | % Increase / (Decrease) | ||||||||||||
| September 27, 2020 | September 29, 2019 | Total Revenue Growth | Currency Impact | Constant Currency Revenue Growth | |||||||||
| Vascular Access | $ | 475.3 | $ | 446.2 | 6.5 | % | (0.6 | )% | 7.1 | % | |||
| Interventional | 275.7 | 314.9 | (12.4 | )% | (0.3 | )% | (12.1 | )% | |||||
| Anesthesia | 216.2 | 253.1 | (14.6 | )% | (0.6 | )% | (14.0 | )% | |||||
| Surgical | 224.9 | 274.9 | (18.2 | )% | (0.6 | )% | (17.6 | )% | |||||
| Interventional Urology | 196.1 | 201.3 | (2.6 | )% | — | % | (2.6 | )% | |||||
| OEM | 168.6 | 166.1 | 1.5 | % | — | % | 1.5 | % | |||||
| Other | 269.2 | 257.9 | 4.4 | % | (0.6 | )% | 5.0 | % | |||||
| Total | $ | 1,826.0 | $ | 1,914.4 | (4.6 | )% | (0.4 | )% | (4.2 | )% | |||
Third quarter 2020 net revenues from sales of Vascular Access products were
Third quarter 2020 net revenues from sales of Interventional products were
Third quarter 2020 net revenues from sales of Anesthesia products were
Third quarter 2020 net revenues from sales of Surgical products were
Third quarter 2020 net revenues from sales of Interventional Urology products were
Third quarter 2020 net revenues from sales of OEM products were
Third quarter 2020 net revenues from sales of other products were
OTHER FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE METRICS
Depreciation expense, amortization of intangible assets and deferred financing charges for the nine months ended September 27, 2020 totaled
Cash and cash equivalents at September 27, 2020 were
Net accounts receivable at September 27, 2020 were
Net inventories at September 27, 2020 were
CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION
As previously announced, Teleflex will comment on its financial results on a conference call to be held today at 8:00 a.m. (ET). The call will be available live and archived on the Company’s website at www.teleflex.com and the accompanying presentation will be posted prior to the call. An audio replay will be available until November 3, 2020 at 11:00am (ET), by calling 855-859-2056 (U.S./Canada) or 404-537-3406 (International), Passcode: 4987865.
ADDITIONAL NOTES
References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.
In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.
Certain financial information is presented on a rounded basis, which may cause minor differences.
Segment results and commentary exclude the impact of discontinued operations.
NOTES ON NON-GAAP FINANCIAL MEASURES
We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP.” In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: constant currency revenue growth and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.
Tables reconciling changes in historical constant currency net revenues to historical GAAP net revenues are set forth above under “Net Revenue by Segment" and "Net Revenue by Global Product Category". Tables reconciling historical adjusted diluted earnings per share from continuing operations to historical GAAP diluted earnings per share from continuing operations are set forth below.
Constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.
Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.
Restructuring, restructuring related and impairment items - Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program. Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.
Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; legal entity restructuring expense; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.
Other items - These are discrete items that occur sporadically and can affect period-to-period comparisons. See footnote C to the reconciliation tables set forth below.
European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. Manufacturers of currently marketed medical devices will have until May 2020 to meet the MDR requirements, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until May 2024, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).
Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.
Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.
| RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS Dollars in millions, except per share amounts | |||||||||||||||||||||||||||||||
| Quarter Ended - September 27, 2020 | |||||||||||||||||||||||||||||||
| Cost of goods sold | Selling, general and administrative expenses | Research and development expenses | Restructuring and impairment charges | (Gain)/Loss on sale of business and assets | Income taxes | Income (loss) from continuing operations | Diluted earnings per share from continuing operations | ||||||||||||||||||||||||
| GAAP Basis | $ | 299.0 | $ | 171.7 | $ | 29.2 | $ | (3.7 | ) | $ | — | $ | (1.0 | ) | $ | 116.6 | $ | 2.46 | |||||||||||||
| Adjustments | |||||||||||||||||||||||||||||||
| Restructuring, restructuring related and impairment items (A) | 7.5 | 0.2 | — | (3.7 | ) | — | (0.5 | ) | 4.6 | $ | 0.10 | ||||||||||||||||||||
| Acquisition, integration and divestiture related items (B) | 1.6 | (23.4 | ) | — | — | — | 0.1 | (21.9 | ) | $ | (0.46 | ) | |||||||||||||||||||
| Other items (C) | — | 0.2 | — | — | — | 0.0 | 0.2 | $ | 0.00 | ||||||||||||||||||||||
| MDR (D) | — | — | 3.0 | — | — | 0.0 | 3.0 | $ | 0.06 | ||||||||||||||||||||||
| Intangible amortization expense (E) | 21.2 | 18.7 | 0.1 | — | — | 6.3 | 33.7 | $ | 0.71 | ||||||||||||||||||||||
| Tax adjustments | — | — | — | — | — | 4.9 | (4.9 | ) | $ | (0.10 | ) | ||||||||||||||||||||
| Adjusted basis | $ | 268.7 | $ | 175.9 | $ | 26.1 | $ | — | $ | — | $ | 9.9 | $ | 131.2 | $ | 2.77 | |||||||||||||||
| RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS Dollars in millions, except per share amounts | ||||||||||||||||||||||||||||
| Quarter Ended - September 29, 2019 | ||||||||||||||||||||||||||||
| Cost of goods sold | Selling, general and administrative expenses | Research and development expenses | Restructuring and impairment charges | (Gain)/Loss on sale of business and assets | Income taxes | Income (loss) from continuing operations | Diluted earnings per share from continuing operations | |||||||||||||||||||||
| GAAP Basis | $ | 293.2 | $ | 209.3 | $ | 28.0 | $ | 1.3 | $ | (1.1 | ) | $ | (130.4 | ) | $ | 228.9 | $ | 4.85 | ||||||||||
| Adjustments | ||||||||||||||||||||||||||||
| Restructuring, restructuring related and impairment items (A) | 4.3 | — | — | 1.3 | — | 0.7 | 4.9 | $ | 0.10 | |||||||||||||||||||
| Acquisition, integration and divestiture related items (B) | 0.1 | 15.6 | — | — | (1.1 | ) | — | 14.7 | $ | 0.31 | ||||||||||||||||||
| Other items (C) | — | (0.9 | ) | — | — | — | (0.2 | ) | (0.7 | ) | $ | (0.01 | ) | |||||||||||||||
| MDR (D) | — | — | 1.0 | — | — | — | 1.0 | $ | 0.02 | |||||||||||||||||||
| Intangible amortization expense (E) | 20.6 | 16.7 | 0.1 | — | — | 7.6 | 29.8 | $ | 0.63 | |||||||||||||||||||
| Tax adjustments | — | — | — | — | — | 138.4 | (138.4 | ) | $ | (2.93 | ) | |||||||||||||||||
| Adjusted basis | $ | 268.3 | $ | 177.9 | $ | 26.8 | $ | — | $ | — | $ | 16.0 | $ | 140.2 | $ | 2.97 | ||||||||||||
- Restructuring, restructuring related and impairment items - For the three months ended September 27, 2020, pre-tax restructuring credits were
$3.7million , pre-tax restructuring related charges were$7.7 million ; and there were no pre-tax impairment charges. For the three months ended September 29, 2019, pre-tax restructuring charges were$1.3 million , pre-tax restructuring related charges were$4.3 million ; and there were no pre-tax impairment charges. - Acquisition, integration and divestiture related items - For the three months ended September 27, 2020, these items primarily related to contingent consideration liabilities; reversal of previously recognized income related to a distributor conversion in Japan; and charges primarily related to our acquisition of Z-Medica, LLC. For the three months ended September 29, 2019, these charges primarily related to contingent consideration liabilities; and our acquisition of Essential Medical, Inc., partially offset by the gain on sale of an asset. There were no divestiture related activities for the three months ended September 27, 2020 or September 29, 2019.
- Other items - For the three months ended September 27, 2020, other items included expenses associated with prior year tax matters. For the three months ended September 29, 2019, other items included debt modification costs and product relabeling costs, offset by a credit associated with an insurance settlement.
- MDR - These costs were associated with our efforts to comply with the European Medical Device Regulation.
- Intangible amortization expense - For the three months ended September 27, 2020 and September 29, 2019, we reclassified intangible asset amortization expense of
$21.2 million and$20.6 million , respectively, from selling, general and administrative expenses to cost of goods sold.
| RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS Dollars in millions, except per share amounts | |||||||||||||||||||||||||||
| Year to Date Ended - September 27, 2020 | |||||||||||||||||||||||||||
| Cost of goods sold | Selling, general and administrative expenses | Research and development expenses | Restructuring and impairment charges | (Gain)/Loss on sale of business and assets | Income taxes | Income (loss) from continuing operations | Diluted earnings per share from continuing operations | ||||||||||||||||||||
| GAAP Basis | 884.7 | 510.7 | 86.0 | 16.7 | — | 22.0 | 259.2 | $ | 5.48 | ||||||||||||||||||
| Adjustments | |||||||||||||||||||||||||||
| Restructuring, restructuring related and impairment items (A) | 18.8 | 0.5 | — | 16.7 | — | 1.1 | 34.8 | $ | 0.74 | ||||||||||||||||||
| Acquisition, integration and divestiture related items (B) | 3.3 | (50.8 | ) | — | — | — | 0.7 | (48.2 | ) | $ | (1.02 | ) | |||||||||||||||
| Other items (C) | — | 0.5 | — | — | — | 0.1 | 0.4 | $ | 0.01 | ||||||||||||||||||
| MDR (D) | — | — | 7.4 | — | — | 0.0 | 7.4 | $ | 0.16 | ||||||||||||||||||
| Intangible amortization expense (E) | 63.2 | 55.1 | 0.3 | — | — | 18.9 | 99.7 | $ | 2.11 | ||||||||||||||||||
| Tax adjustments | — | — | — | — | — | 2.6 | (2.6 | ) | $ | (0.05 | ) | ||||||||||||||||
| Adjusted basis | $ | 799.4 | $ | 505.3 | $ | 78.2 | $ | — | $ | — | $ | 45.4 | $ | 350.8 | $ | 7.42 | |||||||||||
| RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS Dollars in millions, except per share amounts | |||||||||||||||||||||||||||
| Year to Date Ended - September 29, 2019 | |||||||||||||||||||||||||||
| Cost of goods sold | Selling, general and administrative expenses | Research and development expenses | Restructuring and impairment charges | (Gain)/Loss on sale of business and assets | Income taxes | Income (loss) from continuing operations | Diluted earnings per share from continuing operations | ||||||||||||||||||||
| GAAP Basis | 883.1 | 631.7 | 82.7 | 20.3 | (3.8 | ) | (115.6 | ) | 354.2 | $ | 7.53 | ||||||||||||||||
| Adjustments | |||||||||||||||||||||||||||
| Restructuring, restructuring related and impairment items (A) | 10.9 | — | — | 20.3 | — | 4.1 | 27.3 | $ | 0.58 | ||||||||||||||||||
| Acquisition, integration and divestiture related items (B) | 0.1 | 41.8 | — | — | (3.8 | ) | (1.9 | ) | 40.0 | $ | 0.85 | ||||||||||||||||
| Other items (C) | — | 1.5 | — | — | — | 0.4 | 1.2 | $ | 0.03 | ||||||||||||||||||
| MDR (D) | — | — | 1.6 | — | — | — | 1.6 | $ | 0.03 | ||||||||||||||||||
| Intangible amortization expense (E) | 62.1 | 50.3 | 0.3 | — | — | 23.0 | 89.6 | $ | 1.91 | ||||||||||||||||||
| Tax adjustments | — | — | — | — | — | 143.6 | (143.6 | ) | $ | (3.05 | ) | ||||||||||||||||
| Adjusted basis | $ | 810.1 | $ | 538.0 | $ | 80.7 | $ | — | $ | — | $ | 53.6 | $ | 370.3 | $ | 7.87 | |||||||||||
- Restructuring, restructuring related and impairment items - For the nine months ended September 27, 2020, pre-tax restructuring charges were
$16.7 million , pre-tax restructuring related charges were$19.2 million ; and there were no pre-tax impairment charges. For the nine months ended September 29, 2019, pre-tax restructuring charges$13.4 million , pre-tax restructuring related charges were$11.0 million , and pre-tax impairment charges were$6.9 million . - Acquisition, integration and divestiture related items - For the nine months ended September 27, 2020, these items primarily related to the reversal of contingent consideration liabilities, partially offset by charges primarily related to our acquisitions of HPC and Z-Medica, LLC and the reversal of previously recognized income related to a distributor conversion in Japan. For the nine months ended September 29, 2019, these charges primarily related to contingent consideration liabilities and our acquisition of Essential Medical, Inc., partially offset by the gain on sale of a business and another asset. There were no divestiture related activities for the nine months ended September 27, 2020 or September 29, 2019.
- Other items - For the nine months ended September 27, 2020, other items included expenses associated with prior year tax matters. For the nine months ended September 29, 2019, other items included debt modification costs, expenses associated with a franchise tax audit, and product relabeling costs, somewhat offset by a credit associated with an insurance settlement.
- MDR - These costs were associated with our efforts to comply with the European Medical Device Regulation.
- Intangible amortization expense - For the nine months ended September 27, 2020 and September 29, 2019, we reclassified intangible asset amortization expense of
$63.2 million and$62.1 million , respectively, from selling, general and administrative expenses to cost of goods sold.
ABOUT TELEFLEX INCORPORATED
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift®, and Weck® - trusted brands united by a common sense of purpose.
CAUTION CONCERNING FORWARD-LOOKING INFORMATION
This press release contains forward-looking statements, including, but not limited to, our belief that we will see sequential improvement in our financial results during the fourth quarter of 2020 as compared to our results for the third quarter of 2020; and our expectation that our acquisition of Z-Medica will be accretive to our adjusted earnings per share in 2021. Actual results could differ materially from those in the forward-looking statements due to, among other things, the adverse economic conditions associated with the COVID-19 global health pandemic and the associated financial crisis, stay-at-home and other orders, which may significantly reduce customer spending and which may have a negative impact on the Company’s business, changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; the inability of acquired businesses to generate revenues in accordance with our expectations; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; risks related to our acquisition of Z-Medica, including among other items, the possibility the acquisition does not close, unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the transaction, unanticipated difficulties and expenditures in connection with integration programs, customer and shareholder reaction to the transaction, unknown liabilities and the risk of regulatory actions related to the proposed acquisition; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, sovereign debt issues and the impact of the United Kingdom's departure from the European Union, commonly known as "Brexit"; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.
| TELEFLEX INCORPORATED CONSOLIDATED STATEMENTS OF INCOME | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 27, 2020 | September 29, 2019 | September 27, 2020 | September 29, 2019 | |||||||||||||
| (Dollars and shares in thousands, except per share) | ||||||||||||||||
| Net revenues | $ | 628,301 | $ | 648,319 | $ | 1,825,977 | $ | 1,914,410 | ||||||||
| Cost of goods sold | 298,977 | 293,244 | 884,657 | 883,127 | ||||||||||||
| Gross profit | 329,324 | 355,075 | 941,320 | 1,031,283 | ||||||||||||
| Selling, general and administrative expenses | 171,673 | 209,291 | 510,662 | 631,712 | ||||||||||||
| Research and development expenses | 29,218 | 27,984 | 85,978 | 82,729 | ||||||||||||
| Restructuring and impairment (credits) charges | (3,659 | ) | 1,268 | 16,692 | 20,348 | |||||||||||
| Gain on sale of assets | — | (1,089 | ) | — | (3,828 | ) | ||||||||||
| Income from continuing operations before interest and taxes | 132,092 | 117,621 | 327,988 | 300,322 | ||||||||||||
| Interest expense | 16,652 | 19,545 | 47,773 | 62,995 | ||||||||||||
| Interest income | (214 | ) | (470 | ) | (956 | ) | (1,281 | ) | ||||||||
| Income from continuing operations before taxes | 115,654 | 98,546 | 281,171 | 238,608 | ||||||||||||
| (Benefit) taxes on income from continuing operations | (951 | ) | (130,383 | ) | 21,971 | (115,567 | ) | |||||||||
| Income from continuing operations | 116,605 | 228,929 | 259,200 | 354,175 | ||||||||||||
| Operating loss from discontinued operations | (29 | ) | (9 | ) | (11 | ) | (1,291 | ) | ||||||||
| Tax benefit on operating loss from discontinued operations | (11 | ) | (9 | ) | (4 | ) | (317 | ) | ||||||||
| Loss from discontinued operations | (18 | ) | — | (7 | ) | (974 | ) | |||||||||
| Net income | $ | 116,587 | $ | 228,929 | $ | 259,193 | $ | 353,201 | ||||||||
| Earnings per share: | ||||||||||||||||
| Basic: | ||||||||||||||||
| Income from continuing operations | $ | 2.51 | $ | 4.95 | $ | 5.58 | $ | 7.67 | ||||||||
| Loss from discontinued operations | — | — | — | (0.02 | ) | |||||||||||
| Net income | $ | 2.51 | $ | 4.95 | $ | 5.58 | $ | 7.65 | ||||||||
| Diluted: | ||||||||||||||||
| Income from continuing operations | $ | 2.46 | $ | 4.85 | $ | 5.48 | $ | 7.53 | ||||||||
| Loss from discontinued operations | — | — | — | (0.02 | ) | |||||||||||
| Net income | $ | 2.46 | $ | 4.85 | $ | 5.48 | $ | 7.51 | ||||||||
| Weighted average common shares outstanding | ||||||||||||||||
| Basic | 46,530 | 46,248 | 46,451 | 46,156 | ||||||||||||
| Diluted | 47,333 | 47,176 | 47,269 | 47,051 | ||||||||||||
| TELEFLEX INCORPORATED CONSOLIDATED BALANCE SHEETS | |||||||
| September 27, 2020 | December 31, 2019 | ||||||
| (Dollars in thousands) | |||||||
| ASSETS | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 347,480 | $ | 301,083 | |||
| Accounts receivable, net | 390,476 | 418,673 | |||||
| Inventories | 526,125 | 476,557 | |||||
| Prepaid expenses and other current assets | 101,452 | 97,943 | |||||
| Prepaid taxes | 55,028 | 12,076 | |||||
| Total current assets | 1,420,561 | 1,306,332 | |||||
| Property, plant and equipment, net | 445,242 | 430,719 | |||||
| Operating lease assets | 102,924 | 113,160 | |||||
| Goodwill | 2,363,837 | 2,245,305 | |||||
| Intangible assets, net | 2,228,930 | 2,156,285 | |||||
| Deferred tax assets | 4,915 | 5,572 | |||||
| Other assets | 46,879 | 52,447 | |||||
| Total assets | $ | 6,613,288 | $ | 6,309,820 | |||
| LIABILITIES AND EQUITY | |||||||
| Current liabilities | |||||||
| Current borrowings | $ | 91,750 | $ | 50,000 | |||
| Accounts payable | 96,917 | 102,916 | |||||
| Accrued expenses | 117,493 | 100,466 | |||||
| Current portion of contingent consideration | 4,744 | 148,090 | |||||
| Payroll and benefit-related liabilities | 98,828 | 115,981 | |||||
| Accrued interest | 22,547 | 5,514 | |||||
| Income taxes payable | 10,873 | 6,692 | |||||
| Other current liabilities | 32,095 | 33,396 | |||||
| Total current liabilities | 475,247 | 563,055 | |||||
| Long-term borrowings | 2,035,823 | 1,858,943 | |||||
| Deferred tax liabilities | 486,350 | 439,558 | |||||
| Pension and postretirement benefit liabilities | 55,795 | 82,719 | |||||
| Noncurrent liability for uncertain tax positions | 12,562 | 10,294 | |||||
| Noncurrent contingent consideration | 16,872 | 71,818 | |||||
| Noncurrent operating lease liabilities | 91,379 | 101,372 | |||||
| Other liabilities | 203,057 | 202,741 | |||||
| Total liabilities | 3,377,085 | 3,330,500 | |||||
| Commitments and contingencies | |||||||
| Total shareholders' equity | 3,236,203 | 2,979,320 | |||||
| Total liabilities and shareholders' equity | $ | 6,613,288 | $ | 6,309,820 | |||
| TELEFLEX INCORPORATED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| Nine Months Ended | |||||||
| September 27, 2020 | September 29, 2019 | ||||||
| (Dollars in thousands) | |||||||
| Cash flows from operating activities of continuing operations: | |||||||
| Net income | $ | 259,193 | $ | 353,201 | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
| Loss from discontinued operations | 7 | 974 | |||||
| Depreciation expense | 51,329 | 47,286 | |||||
| Intangible asset amortization expense | 118,649 | 112,661 | |||||
| Deferred financing costs and debt discount amortization expense | 3,191 | 3,313 | |||||
| Gain on sale of assets | — | (3,828 | ) | ||||
| Fair value step up of acquired inventory sold | 1,707 | — | |||||
| Changes in contingent consideration | (54,585 | ) | 40,894 | ||||
| Impairment of long-lived assets | — | 6,911 | |||||
| Stock-based compensation | 14,759 | 20,037 | |||||
| Deferred income taxes, net | 2,600 | (140,963 | ) | ||||
| Payments for contingent consideration | (79,771 | ) | (26,092 | ) | |||
| Interest benefit on swaps designated as net investment hedges | (14,488 | ) | (13,820 | ) | |||
| Other | (15,703 | ) | (7,142 | ) | |||
| Changes in assets and liabilities, net of effects of acquisitions and disposals: | |||||||
| Accounts receivable | 35,546 | (41,221 | ) | ||||
| Inventories | (38,096 | ) | (53,259 | ) | |||
| Prepaid expenses and other assets | 9,393 | (13,184 | ) | ||||
| Accounts payable, accrued expenses and other liabilities | (4,243 | ) | 31,631 | ||||
| Income taxes receivable and payable, net | (48,000 | ) | (28,232 | ) | |||
| Net cash provided by operating activities from continuing operations | 241,488 | 289,167 | |||||
| Cash flows from investing activities of continuing operations: | |||||||
| Expenditures for property, plant and equipment | (62,369 | ) | (83,797 | ) | |||
| Proceeds from sale of assets | 400 | 3,135 | |||||
| Payments for businesses and intangibles acquired, net of cash acquired | (266,843 | ) | (1,265 | ) | |||
| Net interest proceeds on swaps designated as net investment hedges | 9,986 | 8,330 | |||||
| Net cash used in investing activities from continuing operations | (318,826 | ) | (73,597 | ) | |||
| Cash flows from financing activities of continuing operations: | |||||||
| Proceeds from new borrowings | 1,013,807 | 25,000 | |||||
| Reduction in borrowings | (788,807 | ) | (185,500 | ) | |||
| Debt extinguishment, issuance and amendment fees | (8,440 | ) | (4,964 | ) | |||
| Net proceeds from share based compensation plans and the related tax impacts | 11,177 | 14,014 | |||||
| Payments for contingent consideration | (64,135 | ) | (112,006 | ) | |||
| Dividends paid | (47,384 | ) | (47,071 | ) | |||
| Net cash provided by (used in) financing activities from continuing operations | 116,218 | (310,527 | ) | ||||
| Cash flows from discontinued operations: | |||||||
| Net cash (used in) provided by operating activities | (540 | ) | 2,651 | ||||
| Net cash (used in) provided by discontinued operations | (540 | ) | 2,651 | ||||
| Effect of exchange rate changes on cash and cash equivalents | 8,057 | (7,311 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | 46,397 | (99,617 | ) | ||||
| Cash and cash equivalents at the beginning of the period | 301,083 | 357,161 | |||||
| Cash and cash equivalents at the end of the period | $ | 347,480 | $ | 257,544 | |||
| Contact: | Jake Elguicze Treasurer and Vice President of Investor Relations 610-948-2836 |
FAQ
What were Teleflex's third quarter 2020 revenues?
How much did Teleflex's GAAP diluted EPS decline in Q3 2020?
What was the estimated revenue impact of COVID-19 on Teleflex in Q3 2020?
What growth did Teleflex experience in its Interventional Urology segment?
What acquisition did Teleflex announce in October 2020?
